Premium
A flow cytometric method for detection and enumeration of low‐level, residual red blood cells in platelets and mononuclear cell products
Author(s) -
Santana Julie M.,
Dumont Larry J.
Publication year - 2006
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2006.00829.x
Subject(s) - apheresis , coefficient of variation , platelet , blood cell , plateletpheresis , peripheral blood mononuclear cell , glycophorin , red blood cell , fluorescein isothiocyanate , flow cytometry , detection limit , chemistry , medicine , chromatography , microbiology and biotechnology , immunology , biology , biochemistry , in vitro , quantum mechanics , antigen , fluorescence , physics
BACKGROUND: Conventional automated cell counters cannot accurately count residual red blood cells (rRBCs) that are often present in various blood products. A two‐color flow cytometric method (FC) was validated for detecting and enumerating rRBCs in platelets (PLTs) and mononuclear cell (MNC) products. STUDY DESIGN AND METHODS: PLT and MNC products for PLTs (CD61–fluorescein isothiocyanate) and rRBC (anti‐glycophorin A–phycoerythrin) were double stained, and data were acquired with a flow cytometer. Assay linearity, accuracy, and precision were assessed with a standard‐dilution series of rRBCs. This assay was used to determine the rRBCs of apheresis PLTs collected with Trima Accel (Gambro BCT) and MNC products collected with the COBE Spectra (Gambro BCT). RESULTS: The linear range of this assay in PLT and MNC products is 10 to 2000 RBCs per µL (R 2 = 0.994). FC had a mean intraassay coefficient of variation of 11.8 percent at 34 RBCs per µL. A standard clinical hematology analyzer overestimated rRBCs in MNC products by 1.59 × 10 5 ± 0.7 × 10 5 RBCs per µL. Apheresis PLTs had a median of 17.4 RBCs per µL, with 99.0 percent containing fewer than 90.0 RBCs per µL. CONCLUSIONS: This method for determining rRBCs in blood products is accurate and repeatable with a lower limit of detection adequate to assess currently available blood products. FC should be considered for determining rRBCs in MNC products.